Mira Pharmaceuticals Inc (MIRA)

$0.75 +0.01 (1.54%)
Market Cap 32.68M
Revenue (ttm) 0.00
Net Income (ttm) -10.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 83,800
Avg Vol 90,598
Day's Range N/A - N/A
Shares Out 42.02M
Stochastic %K 55%
Beta 1.54
Analysts Sell
Price Target $11.00

Company Profile

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 786 432 9792
Address:
1200 Brickell Avenue, Suite 1950 #1183, Miami, United States
Jaespresso
Jaespresso Aug. 13 at 2:15 PM
$MIRA
0 · Reply
Gibsa
Gibsa Aug. 13 at 7:50 AM
$MIRA Rises were always hidden behind bad news.
1 · Reply
Jaespresso
Jaespresso Aug. 12 at 1:27 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Aug. 11 at 1:28 PM
$MIRA
0 · Reply
luxm3
luxm3 Aug. 11 at 9:20 AM
$MIRA only the sky is the limit... tp 2.3 easy...
1 · Reply
luxm3
luxm3 Aug. 11 at 9:20 AM
$MIRA only the sky is the limit... tp 2.3 easy...
0 · Reply
Jaespresso
Jaespresso Aug. 10 at 4:30 PM
$MIRA
0 · Reply
luxm3
luxm3 Aug. 7 at 2:19 PM
$MIRA added more 0,68.... see you above 1$....
1 · Reply
Jaespresso
Jaespresso Aug. 7 at 1:49 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Aug. 6 at 5:32 PM
$MIRA
0 · Reply
Latest News on MIRA
Mira reports positive results in 7-day dog study for obesity candidate SKNY-1

2026-08-06T13:38:42.000Z - 7 days ago

Mira reports positive results in 7-day dog study for obesity candidate SKNY-1

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Aug 6, 2026, 8:00 AM EDT - 7 days ago

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Mira Pharmaceuticals provides update on MIRA-55, SKNY-1

2026-07-30T13:36:37.000Z - 14 days ago

Mira Pharmaceuticals provides update on MIRA-55, SKNY-1

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

Jul 30, 2026, 8:00 AM EDT - 14 days ago

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

Mira Pharmaceuticals reports formulation results for MIRA-55

2026-07-10T12:11:09.000Z - 4 weeks ago

Mira Pharmaceuticals reports formulation results for MIRA-55

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

Jul 10, 2026, 8:00 AM EDT - 4 weeks ago

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

Mira Pharmaceuticals reports SKNY-1 formulation results

2026-07-06T13:20:06.000Z - 5 weeks ago

Mira Pharmaceuticals reports SKNY-1 formulation results

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

Jul 6, 2026, 9:00 AM EDT - 5 weeks ago

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

Mira Pharmaceuticals reports preclinical pharmacology data on Mira-55

2026-06-25T12:20:26.000Z - 7 weeks ago

Mira Pharmaceuticals reports preclinical pharmacology data on Mira-55

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

Jun 25, 2026, 8:15 AM EDT - 7 weeks ago

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

Mira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2

2026-06-17T12:22:20.000Z - 2 months ago

Mira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

Jun 17, 2026, 8:00 AM EDT - 2 months ago

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

2026-06-04T12:27:50.000Z - 2 months ago

Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

Jun 4, 2026, 8:00 AM EDT - 2 months ago

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

Mira Pharmaceuticals secures worldwide rights for Ketamir-2

2026-05-27T14:14:46.000Z - 2 months ago

Mira Pharmaceuticals secures worldwide rights for Ketamir-2

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

May 27, 2026, 8:00 AM EDT - 2 months ago

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

Mira Pharmaceuticals management to meet with Maxim

2026-05-26T16:54:44.000Z - 2 months ago

Mira Pharmaceuticals management to meet with Maxim

Mira announces results from Phase 1 trial evaluating Ketamir-2

2026-05-14T16:26:48.000Z - 3 months ago

Mira announces results from Phase 1 trial evaluating Ketamir-2

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

May 14, 2026, 8:00 AM EDT - 3 months ago

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

Mira announces acceptance of peer-reviewed SKNY-1 manuscript

2026-05-13T16:28:17.000Z - 3 months ago

Mira announces acceptance of peer-reviewed SKNY-1 manuscript

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

May 13, 2026, 8:00 AM EDT - 3 months ago

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

Mira reports Mira-55 shows no THC-, Rimonabant-associated CNS side effects

2026-03-23T13:20:25.000Z - 5 months ago

Mira reports Mira-55 shows no THC-, Rimonabant-associated CNS side effects

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Mar 23, 2026, 9:00 AM EDT - 5 months ago

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Mira Pharmaceuticals completes Phase 1 dosing of Ketamir-2

2026-03-04T13:43:05.000Z - 5 months ago

Mira Pharmaceuticals completes Phase 1 dosing of Ketamir-2

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

Mar 4, 2026, 8:00 AM EST - 5 months ago

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

Mira Pharmaceuticals initiates final cohort of Ketamir-2 Phase 1 study

2026-02-03T12:45:38.000Z - 6 months ago

Mira Pharmaceuticals initiates final cohort of Ketamir-2 Phase 1 study

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

Feb 3, 2026, 7:30 AM EST - 6 months ago

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Oct 24, 2025, 7:30 AM EDT - 10 months ago

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Oct 16, 2025, 7:30 AM EDT - 10 months ago

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Sep 30, 2025, 7:30 AM EDT - 11 months ago

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Sep 22, 2025, 8:00 AM EDT - 11 months ago

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Sep 16, 2025, 7:30 AM EDT - 11 months ago

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Sep 12, 2025, 7:30 AM EDT - 11 months ago

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Aug 19, 2025, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

Aug 12, 2025, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

Jul 30, 2025, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

Jul 29, 2025, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

Jul 11, 2025, 8:00 AM EDT - 1 year ago

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Jul 3, 2025, 8:00 AM EDT - 1 year ago

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

Jun 30, 2025, 8:00 AM EDT - 1 year ago

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

Jun 25, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

Jun 18, 2025, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 28, 2025, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 8, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

May 6, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

Apr 23, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 16, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

Apr 1, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Mar 24, 2025, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

Mar 13, 2025, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Mar 4, 2025, 8:00 AM EST - 1 year ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 19, 2024, 9:00 AM EST - 1 year ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Dec 10, 2024, 8:30 AM EST - 1 year ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Nov 20, 2024, 7:44 AM EST - 1 year ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Oct 28, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

Oct 21, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Sep 27, 2024, 7:30 AM EDT - 2 years ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

Sep 18, 2024, 7:00 AM EDT - 2 years ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

Sep 11, 2024, 7:30 AM EDT - 2 years ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

Aug 26, 2024, 8:00 AM EDT - 2 years ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

Aug 19, 2024, 7:30 AM EDT - 2 years ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

Aug 12, 2024, 8:00 AM EDT - 2 years ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

Jul 25, 2024, 7:00 AM EDT - 2 years ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Jul 22, 2024, 8:00 AM EDT - 2 years ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Jaespresso
Jaespresso Aug. 13 at 2:15 PM
$MIRA
0 · Reply
Gibsa
Gibsa Aug. 13 at 7:50 AM
$MIRA Rises were always hidden behind bad news.
1 · Reply
Jaespresso
Jaespresso Aug. 12 at 1:27 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Aug. 11 at 1:28 PM
$MIRA
0 · Reply
luxm3
luxm3 Aug. 11 at 9:20 AM
$MIRA only the sky is the limit... tp 2.3 easy...
1 · Reply
luxm3
luxm3 Aug. 11 at 9:20 AM
$MIRA only the sky is the limit... tp 2.3 easy...
0 · Reply
Jaespresso
Jaespresso Aug. 10 at 4:30 PM
$MIRA
0 · Reply
luxm3
luxm3 Aug. 7 at 2:19 PM
$MIRA added more 0,68.... see you above 1$....
1 · Reply
Jaespresso
Jaespresso Aug. 7 at 1:49 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Aug. 6 at 5:32 PM
$MIRA
0 · Reply
Adorno99
Adorno99 Aug. 6 at 2:58 PM
$MIRA way oversold.
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 6 at 1:19 PM
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 $MIRA https://stocktwits.com/news/others/business/mira-reports-positive-7-day-dog-study-results-for-skny-1/cZoJyzTRJ7A
0 · Reply
KPW963
KPW963 Aug. 6 at 12:30 PM
$MIRA
0 · Reply
Namerof69
Namerof69 Aug. 3 at 11:01 PM
$MIRA MIRA Pharmaceuticals has until January 25, 2027, to regain compliance with Nasdaq's minimum bid price requirement.To meet this deadline, MIRA's common stock must close at a bid price of at least $1.00 per share for a minimum of 10 consecutive business days at any point during this 180-day grace period.
4 · Reply
Washingtonstate
Washingtonstate Aug. 3 at 8:46 PM
$MIRA
0 · Reply
KPW963
KPW963 Aug. 3 at 8:31 PM
$MIRA see you tomorrow guys 👊hopefully on some good news !
0 · Reply
KPW963
KPW963 Aug. 3 at 8:13 PM
$MIRA I’m bullish but -20% without a single reason is crazy
1 · Reply
Adorno99
Adorno99 Aug. 3 at 7:58 PM
Why the big drop $MIRA
0 · Reply
luxm3
luxm3 Aug. 3 at 7:58 PM
$MIRA loaded more, but no good situation...
0 · Reply
jonhen
jonhen Aug. 3 at 7:26 PM
$MIRA Lot of volume today. Good or bad?
0 · Reply
Adorno99
Adorno99 Aug. 3 at 6:25 PM
$MIRA Good time to buy!
0 · Reply
Jaespresso
Jaespresso Jul. 31 at 4:27 PM
$MIRA
0 · Reply